We are live on ! Find out more
PRVL

Prevail Therapeutics Inc. Common Stock
PRVL

Delisted

PRVL was delisted on the 21st of January, 2021.

Back to rankings

0 hedge funds and large institutions have $0 invested in Prevail Therapeutics Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 92 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 93 → 0 (-93)

100% less funds holding in top 10

Funds holding in top 10: 2 → 0 (-2)

100% less capital invested

Capital invested by funds: $648M → $0 (-$648M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 92

Holders
–
Holders Change
-93
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
92
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$319M
2
Citadel Advisors
Citadel Advisors
Florida
-$55.8M
3
BlackRock
BlackRock
New York
-$28.4M
4
BC
Boxer Capital
California
-$25.9M
5
AAM
Alpine Associates Management
Florida
-$19.8M
Name Holding Trade Value Shares
Change 		Change in
Stake
WAM
26
Weiss Asset Management
Massachusetts
– -$2.6M -112,827 Closed
Qube Research & Technologies (QRT)
27
Qube Research & Technologies (QRT)
United Kingdom
– -$2.46M -106,544 Closed
VI
28
Vestcor Inc
New Brunswick, Canada
– -$2.31M -100,000 Closed
CS
29
Credit Suisse
Switzerland
– -$2.23M -96,567 Closed
WIC
30
Water Island Capital
New York
– -$2.18M -94,608 Closed
N
31
Nuveen
North Carolina
– -$1.1M -87,660 Closed
LP
32
LMR Partners
United Kingdom
– -$1.85M -80,000 Closed
DCM
33
DAFNA Capital Management
California
– -$1.73M -75,000 Closed
YCM
34
Yakira Capital Management
Connecticut
– -$1.71M -74,056 Closed
AC
35
Aristides Capital
Kentucky
– -$1.61M -70,000 Closed
HM
36
Harvest Management
New York
– -$1.61M -70,000 Closed
Susquehanna International Group
37
Susquehanna International Group
Pennsylvania
– -$1.23M -53,276 Closed
AS
38
Altshuler Shaham
Israel
– -$1.2M -51,933 Closed
Squarepoint
39
Squarepoint
New York
– -$1M -43,430 Closed
CL
40
CSS LLC
Illinois
– -$896K -38,843 Closed
GCP
41
GSA Capital Partners
United Kingdom
– -$824K -35,717 Closed
Bank of New York Mellon
42
Bank of New York Mellon
New York
– -$773K -33,526 Closed
Charles Schwab
43
Charles Schwab
California
– -$768K -33,282 Closed
Wells Fargo
44
Wells Fargo
California
– -$749K -32,479 Closed
California Public Employees Retirement System
45
California Public Employees Retirement System
California
– -$745K -32,305 Closed
WMSA
46
Weiss Multi-Strategy Advisers
New York
– -$717K -31,061 Closed
GI
47
GAMCO Investors
Connecticut
– -$657K -28,500 Closed
Los Angeles Capital Management
48
Los Angeles Capital Management
California
– -$593K -25,705 Closed
VEA
49
Virtus ETF Advisers
New York
– -$544K -23,601 Closed
AllianceBernstein
50
AllianceBernstein
Tennessee
– -$540K -23,400 Closed
1
2
3 4

PRVL Hedge Fund Activity: Q1 2021 in Review

0 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Prevail Therapeutics Inc. Common Stock (PRVL) for Q1 2021, worth a combined $0 — down 100% from $648M a quarter earlier.

Sellers outnumbered buyers: 92 funds closed out of PRVL and 0 opened new positions — a net loss of 92 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was OrbiMed, exiting entirely with an estimated $319M sold.

  • 0 institutional investors held Prevail Therapeutics Inc. Common Stock (PRVL) as of Q1 2021, down from 93 in Q4 2020.
  • Funds reported $0 of Prevail Therapeutics Inc. Common Stock stock for Q1 2021, down 100% quarter-over-quarter.
  • 0 funds opened new Prevail Therapeutics Inc. Common Stock positions in Q1 2021 and 92 closed out, a net change of -92 holders.
  • The largest Prevail Therapeutics Inc. Common Stock seller in Q1 2021 was OrbiMed, an estimated $319M sold.

Based on aggregated 13F filings for Q1 2021.